Meta-analysis of osteoporosis: Fracture risks, medication and treatment

Minerva Medica

Volumn 106, Issue 4, 2015, Pages 203-214

  Liu, W ^a   Yang, L H ^a   Kong, X C ^a   An, L K ^a   Wang, R ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Bisphosphonate therapy; Meta analysis; Osteoporosis

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; STRONTIUM RANELATE; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ALCOHOL ABUSE; ALGORITHM; ARTICLE; ASIAN; BELGIUM; BONE DENSITOMETRY; BONE DENSITY; BONE STRENGTH; CANADA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISORDERS OF STEROID METABOLISM; FRAGILITY FRACTURE; GENDER; GLUCOCORTICOID EXCESS; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INCIDENCE; LIMB FRACTURE; MEDICATION COMPLIANCE; META ANALYSIS; MULTIPLE SCLEROSIS; NETHERLANDS; NORWAY; OSSIFICATION; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIMARY PREVENTION; QUALITY OF LIFE; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SECONDARY OSTEOPOROSIS; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING; SPINE FRACTURE; UNITED STATES; VITAMIN SUPPLEMENTATION; WRIST FRACTURE; AGED; AGING; COMPLICATION; DRUG EFFECTS; EVIDENCE BASED MEDICINE; FEMALE; LIFESTYLE; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; TREATMENT OUTCOME;

AGED; AGING; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LIFE STYLE; MEDICATION ADHERENCE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84961990597     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Trikalinos TA, Salanti G, Zintzaras E, Ioannidis JP. Meta-analysis methods. Adv Genet. 2008; 60: 311-34. doi: 10.1016/S0065-2660(07)00413-0. PMID: 18358326. PubMed.
2. Osteoporosis. www.Disease and conditions. Osteoporosis. Mayo Clinic, USA, 2015.
3. Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14(4): 571-81. doi: 10.1016/j.jval.2010.11.010.
4. Epub 2011 Apr 30. PMID: 21669382. PubMed. 4. McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48: 271-87.
5. J.J. Caro, K.J. Ishak, K.F. Huybrechts, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int, 2004; 15: 1003-1008.
6. E.S. Siris, S.T. Harris, C.J. Rosen, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc, 2006; 81: 1013-1022
7. E.S. Siris, P.L. Selby, K.G. Saag, et al Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med, 2009; 122 (2 Suppl.): S3-S13.
8. C.H. van den Boogaard, N.S. Breekveldt-Postma, S.E. Borggreve, et al. Persistent bisphospho-nate use and the risk of osteoporotic fractures in clinical practice: A database analysis study. Curr Med Res Opin, 2006; 22: 1757-1764.
9. S. de Lusignan, J. van Vlymen, N. Hague, N. Dhoul. Using computers to identify non-com-pliant people at increased risk of osteoporotic fractures in general practice: A cross-sectional study. Osteoporos Int. 2006; 17: 1808-1814.
10. Huybrechts, KF, K.J. Ishak, J.J. Caro. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone.2006; 38: (2006), pp. 922-928
11. S. Adami, G. Isaia, G. Luisetto, et al. Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study.J Bone Miner Res, 21: 1565-1570.
12. D. Weycker, D. Macarios, J. Edelsberg, G. Oster. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporosis Intl. 2007; 18: 271-277.
13. B.A. Briesacher, S.E. Andrade, R.A. Yood, K.H. Kahler. Consequences of poor compliance with bisphosphonates. Bone.2007; 41: 882-887.
14. R. Curtis, A.O. Westfall, H. Cheng, et al. Bisphosphonates adherence and fracture risk: Time-dependent relationships from 103,038 bisphosphonate users in the U.S. JBMR.2007; 22 (Suppl. 1): S440.
15. W.J. Davie, T. Jones, N. Dugard. Compliance with osteoporosis treatment and incidence of hip and wrist fracture after forearm BMD screening. JBMR 2007; 22 (Suppl.1): S457.
16. D.T. Gold, B.C. Martin, J.R. Frytak, et al.A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis Curr Med Res Opin.2007; 23: 585-594.
17. D.T. Gold. Medication adherence: A challenge for patients with post-menopausal osteoporosis and other chronic illnesses. J Manag Care Pharm.2006; 12 (6 Suppl. A): S20-S25.
18. H. Gothe, P. Hadji, A. Hoer, et al. Good persistence and adherence with oral bisphosphonates reduce fracture rate in patients with osteoporotic fractures. Calcified Tissue International, 2007; 80 (Suppl.): S129.
19. S. Jaglal, D. Thiruchelvam, G. Hawker. Impact of adherence to osteoporosis medications on fracture rates: A population-based study. JBMR, 2007; 22 (Suppl. 1): S77.
20. I.Z. Kun, K. Stoica, Z. Szanto, et al. Comparative study of efficiency and adverse effects of three nitrogencontaining bisphosphonates in endocrinology clinic TG-Mures during 2004-2007. Osteoporosis Intl., 2008; 19 (Suppl. 1): S167.
21. F .J. Penning-van Beest, J.A. Erkens, M. Olson, R.M. Herings. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int, 2008; 19: 511-517.
22. S. Perreault, A. Dragomir, L. Blais, et al. Populationbased study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture. Pharmacoepidemiol Drug Safety 2008; 17: 248-259.
23. V. Rabenda, R. Mertens, V. Fabri, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int, 2008; 19: 811-818.
24. V. Rabenda, J.Y. Reginster. Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporosis Intl., 2008; 19 (Suppl. 2): S366.
25. A. Zambon, G. Baio, G. Mazzaglia, et al. Discontinuity and failures of therapy with Bisphosphonates: Joint assessment of predictors with multi-state models. Pharmacoepidemiol Drug Safety, 2008; 17: 260-269.
26. J. Blouin, A. Dragomir, Y. Moride, et al. Impact of noncompliance with alendronate and risedronate on the incidence of non-vertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol, 2008; 66: 117-127.
27. J.R. Curtis, A.O. Westfall, H. Cheng, et al. Benefit of adherence with Bisphosphonates depends on age and fracture type: Results from an analysis of 101,038 new Bisphosphonate users. J Bone Miner Res, 2008; 23: 1435-1441.
28. F .E. Cotte, F. Mercier, P.G. De. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: A retrospective case-control analysis. Clin Ther, 2008; 30: 2410-2422.
29. A.M. Gallagher, S. Rietbrock, M. Olson, T.P. van Staa. Fracture outcomes related to persis-tence and compliance with oral Bisphosphonates. J Bone Miner Res, 2008; 23: 1569-1575.
30. S. Adami, G. Isaia, G. Luisetto, et al. Osteoporosis treatment and fracture incidence: The ICARO longitudinal study. Osteoporosis Intl., 2008; 19: 1219-1223.
31. A.C. Feldstein, D. Weycker, G.A. Nichols, et al. Effectiveness of Bisphosphonate therapy in a community setting. Bone, 2009; 44: (2009), 153-159.
32. S. Rietbrock, M. Olson, T.P. van Staa. The potential effects on fracture outcomes of improvements in persistence and compliance with Bisphosphonates. QJM, 2009; 102: 35-42.
33. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O'Connell D, Cranney A; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in post-menopausal women. Endocr Rev. 8/23. 2002; 4: 529-39. PMID: 12202468[PubMed -indexed for MEDLINE].
34. Tina Willson, Scott D Nelson, Jonathan Newbold, Richard E Nelson, and Joanne LaFleur. The clinical epidemiology of male osteoporosis: A review of the recent literature. Clin. Epidemiol. 2015; 7: 65-76. Publ. online 2015 Jan 9. doi: 10.2147/CLEP.S40966. PMCID: PMC4295898.
35. MacLean C, Newberry S, Maglione M, et al. Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008; 148(3): 197-213. [PubMed].
36. C. Cooper, Z. A. Cole, C. R. Holroyd, S. C. Earl, N. C. Harvey, E. M. Dennison, L. J. Melton, S. R. Cummings, J. A. Kanis. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporosis Intl., 2011; 22 (5): 1277-1288.
37. E. Siris, P. D. Delmas. Assessment of 10-year absolute fracture risk: A new paradigm with worldwide application. Osteoporosis Intl., 2008; 19(4): 383-384.
38. S. Kaptoge, G. Armbrecht, D. Felsenberg, M. Lunt, K. Weber, S. Boonen, I. Jajic, J. J. Stepan, D. Banzer, W. Reisinger. Whom to treat? The contribution of vertebral X-rays to risk-based algo-rithms for fracture prediction. Results from the European Prospective Osteoporosis Study. Osteoporosis Intl., 2006; 17 (9): 1369-1381, Jul 05, 2006.
39. Johnell O, J. A. Kanis. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporosis Intl., 2006; 17 (12): 1726-1733.
40. CADTH's (www.cadth.ca): Wells GA, Cranney A, Boucher M, Peterson J, Shea B, Robinson V, Coyle D, Tugwell P. Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: A meta-analysis, 2015.
41. van Staal T. P., H. G. M. Leufkens and C. Cooper. UK. International Osteoporosis Foundation and National Osteoporosis Foundation. Review Article. The Epidemiology of Corticosteroid-Induced Osteoporosis: AMeta-analysis. Osteoporos Intl., 2002; 13: 777-87.
42. Riku Nikander, Harri Sievänen, Ari Heinonen, Robin M Daly, Kirsti Uusi-Rasi, Pekka Kannus. Targeted exercise against osteoporosis: A systematic review and meta-analysis for optimising bone strength throughout life. BMC Medicine, 2010; 8: 47. http://www.biomedcentral. com/1741-7015/8/47.
43. Shea Beverley, George Wells, Ann Cranney, Nicole Zytaruk, Vivian Robinson, Lauren Griffith, Zulma Ortiz, Joan Peterson, Jonathan Adachi, Peter Tugwell, Gordon Guyatt. The Osteoporosis Methodology Group, and The Osteoporosis Research Advisory Group. VII. Meta-Analysis of Calcium Supplementation for the Prevention of Postmenopausal Osteoporosis. The Endocrine Society, 2001; doi: 10.1210/er.2001-7002.
44. Hermann, AP, Brot C., J. Gramn, N. Kolthoff, and L. Mosekilde. Premenopausal smoking and bone density. J. Bone Mineral Res. 2010; 15(4): First published online: 18 Feb, 2010.
45. Hopkins RB, Ron Goeree, Eleanor Pullenayegum, Jonathan D Adachi, Alexandra Papaio-annou, Feng Xie and Lehana Thabane. Canada. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskeletal Disorders 2011; 12: 209 doi: 10.1186/1471-2474-12-209.